Back to search results

Surgical Systems for Open-Angle Glaucoma

This study is looking back at information from patients who have already received a combination of surgical treatments for open-angle glaucoma. The treatments include Phacoemulsification (a type of cataract surgery), the OMNI Surgical System, and the Hydrus Microstent. Researchers want to see how well these combined procedures lowered eye pressure (IOP) in a diverse group of patients. To be included, you must have a history of these specific surgeries and open-angle glaucoma, with at least three years of follow-up data. The study is measuring the success of these surgical processes over 24 months. The current recruitment status is unclear.

Study design
This is an observational study, meaning researchers are looking at existing patient data. It plans to include 300 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study measures the effectiveness of the surgical process at 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06953349

Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis

Recruiting
Not specifiedAges 18+Observational
Barnet Dulaney Perkins Eye Centers
~300 participants
Updated 2025-05-01 on ClinicalTrials.gov
What's tested:Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Measured Efficacy of Surgical Process with Phacoemulsification
Measured over 24 months

Conditions

Open-Angle Glaucoma

Explore related trials

Open Angle Glaucoma

Where it's being run

1 sites across 1 states
Arizona1

Study leadership

  • Christine Funke, Medical Doctor · PRINCIPAL_INVESTIGATOR · Barnet Dulaney Perkins Eye Centers

Who to contact

Derek J Arnson, Master of Education
[email protected]
4804201005
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects with h/o CEIOL/OMNI/Hydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data
have Glaucoma

Exclusion

Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.
Patients with refractory CME or CME persisting 3 months or more post-operatively
Patients with incomplete IOP, medication logs or VF data within post-operative period
Prior incisional surgery or MIGS

What this trial measures

  • Measured Efficacy of Surgical Process with Phacoemulsification24 months

    Primary endpoint stratified by complete or qualified success: • Proportion of patients with complete success (%) - without the use of medications